Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens

Q4 2025 Management View Brian Lian, President and CEO, highlighted several milestones in 2025, focusing on the obesity pipeline: "With the subcutaneous formulation of our lead molecule, VK2735, ...
Nasdaq

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and ...

MIAMI, FL, June 24, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Monthly Prescribing Reference

Maintenance of Erosive Esophagitis Healing Observed With Tegoprazan

A New Drug Application for the EE and NERD indications for tegoprazan will be submitted in the fourth quarter of 2025. Topline data were announced from the maintenance phase of a phase 3 trial ...
Seeking Alpha

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and ...

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; ...